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Macrophage activation syndrome (MAS) is a secondary
form of haemophagocytic lymphohistiocytosis (HLH)
seen in childhood in the context of rheumatic disease.
MAS is a serious complication to systemic onset juvenile
idiopathic arthritis (SoJIA) with significant morbidity and
mortality.
We present a 12 year old boy admitted to hospital with a
2 week history of fever, malaise, muscle tenderness, and
skin rash. Initially an infection was suspected based on
symptoms and an exceptional high CRP (3717 nmol/l),
however despite antibiotics and a rapidly decreasing CRP
the clinical status deteriorated. The patient became som-
nolent and rigid in all four extremities having weak deep
tendons reflexes. Laboratory studies showed an elevated
CRP (2158 nmol/l), relative pancytopenia, coagulopathy,
high serum ferritin (1254 μmol/l), and increasing liver
transaminases. MRI of the cerebrum showed progressive
lesional changes on T2-weighted FLAIR sequence in the
cortex and basal ganglia. Bone marrow examination was
normal, and did not show hemophagocytosis.
MAS based on SoJIA was suspected and treatment with
cyclosporine A (4 mg/kg/day) and high dose methylpred-
nisolone (12 mg/kg/day for 3 days) was initiated. The
patient did not respond to initial treatment. Anti-TNF-α
monoclonal antibody Infliximab (5 mg/kg) was added to
the treatment and repeated after 2 and 6 weeks. The
patient rapidly improved clinically and biochemically and
went into full recovery after four months.
MAS complicated with severe CNS involvement is associ-
ated with an extremely high mortality rate. Our case sup-
ports the addition of infliximab when standard treatment
fails.
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